Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine

Summary

This was a multinational, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of multiple doses of ESL as prophylactic treatment in subjects with migraine with or without aura. Subjects were randomised in a 1:1:1 ratio to receive placebo, ESL 800 mg/day once daily (QD), or ESL 1200 mg/day QD.

Timeline

Start

2009-04

Primary completion

2010-06

Completion

2010-06

Drugs

Indications